1-4 of 4
Jingsong Yang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor Responses In Vivo

Rocio Montes de Oca, Alireza S. Alavi, Nick Vitali, Sabyasachi Bhattacharya, Christina Blackwell, Krupa Patel, Laura Seestaller-Wehr, Heather Kaczynski, Hong Shi, Eric Dobrzynski, Leslie Obert, Lyuben Tsvetkov, David C. Cooper, Heather Jackson, Paul Bojczuk, Sabrina Forveille, Oliver Kepp, Allan Sauvat, Guido Kroemer, Mark Creighton-Gutteridge, Jingsong Yang, Chris Hopson, Niranjan Yanamandra, Christopher Shelton, Patrick Mayes, Joanna Opalinska, Mary Barnette, Roopa Srinivasan, James Smothers, Axel Hoos
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (10): 1941–1955.
https://doi.org/10.1158/1535-7163.MCT-21-0035
Published: 01 October 2021
View article titled, Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor Responses <em>In Vivo</em>
Open the PDF for Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor Responses <em>In Vivo</em> in another window
Journal Articles

Abstract B88: A selective Raf kinase inhibitor induces cell death and tumor regression of human cancer cell lines encoding B‐RafV600E mutation

Sylvie Laquerre, Marc Arnone, Katherine Moss, Jingsong Yang, Kelly Fisher, Laurie S. Kane‐Carson, Kimberly Smitheman, Jessica Ward, Bradley Heidrich, Tara Rheault, George Adjabeng, Keith Hornberger, John Stellwagen, Alex Waterson, Chao Han, Robert A. Mook, Jr., David Uehling, Alastair J. King
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): B88.
https://doi.org/10.1158/1535-7163.TARG-09-B88
Published: 10 December 2009
View article titled, Abstract B88: A selective Raf kinase inhibitor induces cell death and tumor regression of human cancer cell lines encoding B‐Raf<sup>V600E</sup> mutation
Journal Articles

GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers

Peter Sabbatini, Susan Korenchuk, Jason L. Rowand, Arthur Groy, Qi Liu, Dominic Leperi, Charity Atkins, Melissa Dumble, Jingsong Yang, Kelly Anderson, Ryan G. Kruger, Richard R. Gontarek, Kenneth R. Maksimchuk, Sapna Suravajjala, Russell R. Lapierre, J. Brad Shotwell, Joseph W. Wilson, Stanley D. Chamberlain, Sridhar K. Rabindran, Rakesh Kumar
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (10): 2811–2820.
https://doi.org/10.1158/1535-7163.MCT-09-0423
Published: 12 October 2009
View article titled, GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers
Open the PDF for GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers in another window
Includes: Supplementary data
Journal Articles

GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models

Mary Ann Hardwicke, Catherine A. Oleykowski, Ramona Plant, Jamin Wang, Qiaoyin Liao, Katherine Moss, Ken Newlander, Jerry L. Adams, Dashyant Dhanak, Jingsong Yang, Zhihong Lai, David Sutton, Denis Patrick
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (7): 1808–1817.
https://doi.org/10.1158/1535-7163.MCT-09-0041
Published: 14 July 2009
View article titled, GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models
Open the PDF for GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models in another window